Combining Immunotherapies

Video

Jedd D. Wolchok, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.

Clinical Pearls

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center, discusses ongoing research regarding combinations of immunotherapies.

  • Aphase III study led by MSKaims to compare nivolumab, ipilimumab, and the combination of the drugs in newly diagnosed patients with advanced melanoma.
  • There remains a need to determine the benefits of concurrent combination therapies versus sequenced therapies.
Recent Videos
Related Content
FDA Grants Breakthrough Therapy Designation to Darovasertib in Melanoma

FDA Grants Breakthrough Therapy Designation to Darovasertib in Melanoma

Jordyn Sava
March 31st 2025
Article

A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.

Read More

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More